The Indian Council of Medical Research (ICMR) has taken a significant step towards India’s malaria elimination strategy by initiating the commercialization process of AdFalciVax, a recombinant multi-stage malaria vaccine. This move aims to combat the deadly Plasmodium falciparum parasite and enhance public health.
About the Vaccine: AdFalciVax
- Developed by ICMR-Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB)
- Targets Plasmodium falciparum, the cause of severe malaria
- Aims to reduce community transmission of the parasite
- Recombinant multi-stage vaccine covering various parasite lifecycle phases
Commercialisation and Tech Transfer
- ICMR invites Expressions of Interest (EoI) for technology transfer and production
- Selected partners to receive expert guidance and support from ICMR-RMRCBB
- Collaborative approach to accelerate vaccine availability
Development Timeline
- Expected total development span of at least 7 years in 4 stages
- Each stage includes a 6-month buffer for potential delays
Significance of AdFalciVax
India faces a high burden of malaria cases, particularly from Plasmodium falciparum in tribal and underdeveloped areas. The indigenous vaccine can enhance accessibility, affordability, and reduce reliance on global suppliers. It aligns with India’s goal to eliminate malaria by 2030.
Key Takeaways for Competitive Exams:
- ICMR’s initiative to commercialize AdFalciVax is a significant step in India’s malaria elimination strategy
- AdFalciVax targets Plasmodium falciparum and aims to reduce community transmission of the parasite
- Collaboration with pharmaceutical companies will accelerate vaccine availability and production
- India’s public health goal includes eliminating malaria by 2030
